Abstract
A (213)Bi-labeled antibody to CD74 was evaluated as a therapeutic agent for B-cell lymphoma. The alpha-particle emission, with a half-life of 46 min, is appropriate for therapy of micrometastases. The labeled Ab retained full immunoreactivity, and was potent at single-cell kill of the Raji B-lymphoma cell line. Approximately 30 decays of cell-bound (213)Bi was required for a cell kill of 99%, and dosimetry calculations suggested that the cGy dose delivered was sufficient to produce the level of toxicity observed. A non-reactive control Ab, labeled similarly, also produced toxicity, due to decays occurring in the medium, but was approximately 3-fold less potent than the reactive Ab. In a SCID mouse xenograft micrometastatic model, Ab injection at day 2 or day 5 after tumor inoculation resulted in strong, specific suppression of tumor growth, with some apparent cures.
Publication types
-
Evaluation Study
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Antibodies / immunology
-
Antibodies / therapeutic use*
-
Antigens, Differentiation, B-Lymphocyte / immunology
-
Antigens, Differentiation, B-Lymphocyte / therapeutic use
-
Bismuth / therapeutic use*
-
Cell Line, Tumor / cytology
-
Cell Line, Tumor / pathology
-
Cell Survival / radiation effects*
-
Dose-Response Relationship, Radiation
-
Histocompatibility Antigens Class II / immunology
-
Histocompatibility Antigens Class II / therapeutic use
-
Lymphoma, B-Cell / immunology
-
Lymphoma, B-Cell / pathology
-
Lymphoma, B-Cell / radiotherapy*
-
Mice
-
Mice, SCID
-
Radioimmunotherapy / methods*
-
Radioisotopes / therapeutic use*
-
Radiopharmaceuticals
-
Radiotherapy Dosage
-
Survival
-
Tissue Transplantation
-
Transplantation, Heterologous
-
Treatment Outcome
Substances
-
Antibodies
-
Antigens, Differentiation, B-Lymphocyte
-
Histocompatibility Antigens Class II
-
Radioisotopes
-
Radiopharmaceuticals
-
invariant chain
-
Bismuth